Abstract
Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Current Drug Targets
Title: Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology
Volume: 7 Issue: 8
Author(s): Giovanna Improta and Maria Broccardo
Affiliation:
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Abstract: Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Export Options
About this article
Cite this article as:
Improta Giovanna and Broccardo Maria, Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology, Current Drug Targets 2006; 7 (8) . https://dx.doi.org/10.2174/138945006778019354
DOI https://dx.doi.org/10.2174/138945006778019354 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoid Hyperemesis Syndrome
Current Drug Abuse Reviews Research Strategies for Pain in Lumbar Radiculopathy Focusing on Acid-Sensing Ion Channels and Their Toxins
Current Topics in Medicinal Chemistry The Dynamic TRPA1 Channel: A Suitable Pharmacological Pain Target?
Current Pharmaceutical Biotechnology Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Brain Metabolism of Ethanol and Alcoholism: An Update
Current Drug Metabolism Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Cytokine-Purine Interactions in Traumatic Stress, Behavioral Depression,and Sickness
CNS & Neurological Disorders - Drug Targets The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review
Protein & Peptide Letters Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review
Current Pharmaceutical Design Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies
Current Diabetes Reviews Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Current Medicinal Chemistry The Perfect Storm: The High Prevalence Low Severity Outcomes of the Preterm Survivors
Current Pediatric Reviews Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry